One Sentence Summary: Use of a novel natural antigen processing assay reveals a mechanism for the presentation of shared CD4+ T cell epitopes of topoisomerase-I in immunogenetically diverse patients with scleroderma.
Introduction
Targeting of protein autoantigens by the adaptive immune system is a hallmark feature of autoimmune diseases. As fundamental regulators of cellular and humoral immunity, CD4+ T cells specific for self-proteins are implicated as central pathogenic drivers of these diseases (1) . This is highlighted by high-titer autoantibodies of the IgG subclass, indicative of CD4+ T helper cell involvement, and strong genetic association with specific HLA-DRβ1 alleles observed in many autoimmune disorders. Despite the recognized importance of autoantigen-specific CD4+ T cells in autoimmune disease pathogenesis, our current knowledge of autoreactive T cell epitope specificity is limited, and even less is known about the mechanisms that govern the presentation of autoantigenic epitopes by disease-associated HLA-DR molecules. This lack of understanding is largely due to: 1) the complexity of studying disease in highly heterogeneous human populations;
2) limited access to patient biospecimens; and 3) the low sensitivity and high cost of currently available methods for studying autoreactive T cells in humans. This has led to the reliance on instructive animal models and the widespread use of in silico prediction algorithms or overlapping peptide libraries for defining candidate autoreactive CD4+ T cell epitopes (2, 3) . While informative, these methods cannot recapitulate the nuances of human pathophysiology, highlighting the need to approach autoantigenic CD4+ T cell epitope discovery by studying antigen processing directly in patients.
Scleroderma, also called systemic sclerosis, is a complex autoimmune rheumatic disease of unknown etiology, characterized by widespread vasculopathy, fibrosis of the skin and internal organs (4) , and immunological derangements, including the production of autoantibodies to specific nuclear antigens (5) . No existing animal model fully recapitulates the intricate immunopathology of this condition. Anti-topoisomerase-I (TOP1) autoantibodies (ATA; also known as anti-Scl-70) are present in 20-45% of patients with scleroderma and are associated with diffuse skin involvement, pulmonary fibrosis and high mortality (6) . ATA production in patients with scleroderma is associated with specific HLA-DRB1 alleles, implicating CD4+ T helper cells in driving immune responses to TOP1. TOP1-specific CD4+ T cells have been detected in the peripheral blood of patients with scleroderma (7) (8) (9) (10) , are HLA-DR restricted, and their frequency is associated with the presence, severity, and progression of lung fibrosis (11) . Previous attempts to define TOP1 epitopes in patients with scleroderma using overlapping peptide/protein fragment libraries or peptides derived from in silico prediction have resulted in the identification of scattered epitopes with unspecified biological and clinical significance (7) (8) (9) (10) . Therefore, although ATAassociated HLA-DRB1 alleles have been defined and TOP-I-specific CD4+ T cells have been detected in ATA-positive patients, the identification of the TOP1 epitopes driving the autoimmune process has remained elusive.
To overcome current limitations related to the identification and study of autoreactive T cell epitopes, we developed a method for identifying the repertoire of naturally processed TOP1 peptides presented by antigen presenting cells (APCs) obtained from patients with scleroderma. This approach has innovative features compared to traditional epitope-discovery methods, as it harnesses the cellular MHC class II antigen processing machinery to identify naturally presented peptides, without requiring pre-defined knowledge about the target peptide length or HLA status.
Our analysis of naturally presented TOP1 peptides has revealed unexpected insights into the pathogenesis of scleroderma and identified a discrete set of clinically relevant TOP1-specific CD4+ T cell epitopes that may inform future development of antigen-specific diagnostic and therapeutic tools.
Results

Identification of naturally processed TOP1 peptides
We developed a natural antigen processing assay (NAPA) to identify TOP1 peptides presented by MHC class II molecules expressed on antigen presenting cells (APC) from patients with scleroderma. As a source of patient-specific APCs, monocytes were isolated from the peripheral blood of 6 ATA-positive patients with scleroderma and cultured in the presence of GM-CSF and IL-4 to generate monocyte-derived dendritic cells (mo-DCs). Mo-DCs were then pulsed with the whole TOP1 protein to allow for internalization and processing. HLA-DR-peptide complexes were isolated by immunoprecipitation (experimental workflow outlined in Fig. 1 ). The HLA-DR bound peptides were then eluted, separated by size exclusion, and sequenced by mass spectrometry.
NAPA identified hundreds of naturally processed peptides, deriving from TOP1 as well as from other self-proteins ( Fig. 2 and Table S1 ). The median length of these peptides was 15 amino acids. Clustering into nested sets of variable length peptides around a common core sequence was common (Table S1 ). These are features typical of naturally processed MHC class II peptides, which tend to be 13-25 amino acids long and exist in nested sets (12, 13) . As expected, pathway analysis of the naturally processed peptides showed that the majority of these peptides were derived from proteins involved in antigen processing ( Fig. 2B ). Further analysis of the peptides presented between individuals revealed an enrichment of peptides from proteins expected to traffic through the secretory pathway, where MHC class II antigen processing occurs (Fig. 2C ). These including membrane-associated (e.g. ITGAM and MRC1) and secreted proteins (e.g. TGFBI and TIMP3), as well as other MHC molecules. Importantly, the only antigen commonly presented by all 6 patients was the pulsed antigen TOP1, demonstrating the ability of NAPA to detect peptides from exogenous proteins. The specificity of NAPA for detecting HLA-DR-bound peptides, including those derived from TOP1, was confirmed using unpulsed mo-DCs and isotype control antibodies for immunoprecipitation (Tables S2 and S3 ). In these experimental conditions, no TOP1 peptides were detected.
Remarkably, we observed a substantial overlap in TOP1 peptides presented by ATApositive scleroderma patients, with all subjects presenting peptides originating from only 10 discrete 13-23 amino acid long regions of the TOP1 molecule (Fig. 3A) . The median number of putative regions presented by each individual patient was 4 (range 1-7), and 70% were presented by at least two subjects. The 10 regions from which TOP1 peptides were presented are from diverse domains in the TOP1 protein and largely reside within structural elements, most dominantly alpha helices flanked by unstructured loops on the surface of the TOP1 protein ( Fig.3A and B). The localization of putative TOP1 epitopes within structural elements adjacent to flexible loops is similar to what has been observed for CD4+ T cell epitopes derived from other infectious and self-antigens (14, 15) . Using NAPA, we successfully identified a common set of TOP1 peptides derived from the whole TOP1 protein, which were naturally processed and presented by HLA-DR molecules in mo-DCs generated ex vivo from patients with ATA-positive scleroderma.
Shared motifs present in HLA-DRβ chains of patients with ATA-positive scleroderma
We next performed HLA immunogenetic analysis to determine if the presentation of common TOP1 peptides identified in our patients was due to the presence of shared HLA-DRB1 alleles. Despite the known association of ATA with specific HLA-DRB1 alleles (i.e. HLA-DRB1*11:01, *11:04, *08:02, *08:04, or *15:02)(16), only 3 subjects (50%) harbored a previously defined risk allele. While these 3 patients concurrently presented peptides from more regions of the TOP1 molecule compared to those who did not exhibit a known ATA-associated HLA-DRB1 allele (median 6 vs. 1), common peptides were presented regardless of the allele status.
Given this unexpected ability of diverse HLA-DR variants to present common TOP1 peptides, we sought to determine if similar features were present in the HLA-DRβ chains of ATApositive scleroderma patients. To explore this, we performed amino acid sequence alignment of the HLA-DRβ variants linked to the development of ATA-positive scleroderma (16) HLA-DRβ1*15:02, associated with ATA in Asian populations (16) , had a similar 67 I-L-E-Q-A-R-A-A 74 motif but a distinct sequence at position 9-14 ( 9 W-Q-P-K-R-E 14 ) ( Fig. 4A ). Importantly, these two motifs contain key peptide contact residues at positions 9, 11, 13, 14 and 67, 70, 71, 74 respectively ( Fig. 4B ).
Analysis of the HLA-DRβ chains present in patients who did not have previously defined ATA-associated HLA-DRB1 alleles, but were able to present common TOP1 peptides, revealed several conserved features. HLA-DRβ1*15:01 and *16:01 contained motifs at positions 9-14 and 67-74 that were identical to known ATA-associated alleles ( Fig. 4A ). HLA-DRβ1*04:01 and *04:02 were less similar, but had conserved amino acids at known peptide contact positions (i.e. 9, 14, and 67, 70, 74). A more detailed analysis of β-chain residues that comprise the five major peptide binding pockets in the HLA-DR groove (denoted as P1, P4, P6, P7, and P9) confirmed that ATA-associated and homologous alleles have highly similar peptide binding pockets ( Fig. 4C ).
Interestingly, HLA-DRβ1*09:01 and *07:01 were divergent from ATA-associated alleles at several critical peptide contact residues ( Fig. 4 , A and C). HLA-DRβ1*07:01 has been reported to be protective against scleroderma development (21) . While all the ATA-positive patients in our study possessed at least one allele that contained ATA-associated motifs, those who harbored HLA-DRβ1*09:01 and *07:01 presented the fewest number of TOP1 peptides (Fig. 3A) . These data reveal shared features in the peptide binding grooves of seemingly unrelated HLA-DRβ1 variants present in ATA-positive patients affected by scleroderma, highlighting their ability to present a common set of TOP1 peptides.
Promiscuous binding of TOP1 peptides to multiple HLA-DR variants
To examine the intermolecular interactions between the commonly presented TOP1 peptides identified using NAPA and the HLA-DR variants detected in these patients, we used the NetMHCII 2.3 algorithm to predict the peptide binding affinity and register (22) . Since all of the patients were heterozygous at the HLA-DRB1 locus, we examined the predicted binding of peptides to both HLA-DR variants present in a given individual. This analysis revealed peptides that could be categorized into two distinct groups, termed group A and B, based on their predicted binding register ( Fig. 5 ). Group A peptides (peptides 1, 2, 8, 9, and 10) were predicted to bind in the same register to all associated HLA-DR variants. This is in contrast to group B peptides, which were predicted to bind in different registers to multiple different HLA-DR variants. Group A peptides were also predicted to bind with significantly lower affinity to their respective HLA-DR molecules than Group B peptides (peptides 3, 4, 5, 6, and 7) (4421 ± 1184 vs. 535 ± 276 nM; p=0.013), and were presented by fewer individuals than group B peptides (median 1 vs. 3). This suggests that group A peptides are relatively weak-binding peptides that contain a single core epitope (e.g. LMKLEVQAT in peptide 10), whose anchor residues interact with shared features present in the HLA-DR binding grooves of patients with ATA. In contrast, group B peptides appear to contain multiple distinct epitopes, each possessing a unique set of anchor residues that enable high-affinity interaction with a more diverse set of HLA-DR binding pockets (e.g. LSYNRANRA, ILSYNRANR, and YNRANRAVA in peptide 7). Taken together, these data support a model of convergent TOP1 peptide presentation in patients with scleroderma driven by shared peptidebinding motifs in the HLA-DR groove and a promiscuous group of TOP1 peptides.
Robust recognition of commonly presented TOP1 epitopes by CD4+ T cells in scleroderma
The discovery of a shared mechanism for the presentation of a core set of TOP1 peptides suggests that these epitopes may be central to the disease process in patients with scleroderma. To determine if these epitopes are immunologically relevant and recognized in ATA-positive patients, we synthesized 10 peptides corresponding to the putative TOP1 epitopes identified using NAPA ( Fig. 3A ; Table 1 ) and examined their ability to stimulate CD4+ T cells from 11 ATA-positive and 11 ATA-negative scleroderma patients (clinical variables are shown in Table S4 ). CD4+ T cell activation, as measured by upregulation of the early activation marker CD154 (11, 23) , was observed in response to at least one TOP1 peptide in 73% (8/11) of ATA-positive patients compared to 27% (3/11) of ATA-negative individuals ( Figure 6A , Table S5 ). ATA-positive patients also responded concurrently to significantly more TOP1 peptides (median 2 vs. 0; p=0.02) ( Fig. 6B ), particularly ATA-positive subjects with known disease-associated HLA-DRB1 alleles (median 7 vs. 1.5). Recognition of group A and B peptides was observed regardless of ATAassociated allele status. For 6 out of the 11 ATA-positive patients (54%), the combined frequency of CD154+ cells observed in response to the individual TOP1 peptides (Fig. S1 ) was comparable to that measured in response to the whole TOP1 protein, suggesting the immunodominance of these 10 naturally processed TOP1 peptides in these individuals. Robust recognition of this core set of TOP1 peptides in immunogenetically diverse ATA-positive patients, supports our observation that features on both sides of the peptide-MHC interaction contribute to the development of a meaningful anti-TOP1 immune responses in patients with scleroderma.
Diversity of TOP1-specific T cell responses associated with ILD severity
Given the breadth of the TOP1-specific CD4+T cell response across multiple commonly presented epitopes and known association of TOP1-specific CD4+ T cell frequency with ILD(11), we examined whether the number of TOP1-epitopes recognized was associated with the severity of ILD in ATA-positive patients with scleroderma. We evaluated the lowest forced vital capacity (FVC) recorded during the course of clinical follow-up for each patient as a measure of the severity of lung fibrosis. We focused this analysis on the 9 ATA-positive patients with radiographically defined scleroderma-associated ILD. A significant negative association was observed between the minimum FVC and the number of TOP1 epitopes that elicited a T cell response (p=0.025; Fig.   7A ). While this relationship was also observed in response to whole TOP1 protein (p=0.002; Fig.   7B ), it is remarkable that these 10 commonly presented epitopes were sufficient to identify T cell responses associated with more severe lung disease. This implicates CD4+ T cells targeting commonly presented TOP1 epitopes in the pathogenesis of scleroderma-ILD.
Discussion
Our study supports a mechanism for how immunogenetically diverse patients affected by the autoimmune disease scleroderma can develop convergent immunologic and phenotypic characteristics. We have successfully developed and employed a robust method for the identification of biologically relevant naturally processed TOP1-specific CD4+ T cell autoantigenic epitopes leveraging antigen-presenting cells obtained directly from patients. Our data show that the presentation of a common set of TOP1 epitopes is shared by individuals with distinct HLA-DR variants and define how unique features present on both sides of the "peptide-HLA-DR interaction" synergize to drive this process. These findings, together with the observation that the breadth of the CD4+ T cell responses to these TOP1 epitopes is associated with presence and severity of lung fibrosis, offer novel insights into the pathogenesis of scleroderma.
Our study has shed light on one of the most proximal events in the stimulation of autoreactive TOP1-specific T cells, the presentation of autoantigenic epitopes by ATA-associated HLA-DR variants. We identified shared motifs in the peptide binding grooves of seemingly unrelated HLA-DR variants found in patients with ATA-positive scleroderma ( 9 E-Y-S-T-S/G-E 14 and 67 F-L-E-D-R-A-A/L 74 ) that enabled the presentation of a common set of TOP1 epitopes.
Importantly, the 67 F-L-E-D-R 71 motif was previously identified by Kuwana et al. in 1993 and hypothesized to be a common feature of alleles associated with ATA in different ethnicities (18, 19, 24) , but the mechanism for this was unknown. Our data provide direct evidence that the presence of HLA-DR alleles containing this or homologous sequences is associated with the amplified presentation of a higher number of TOP1 peptides as well as with autoreactive CD4+ T cell responses directed towards multiple TOP1 epitopes. The finding in scleroderma patients of shared motifs in seemingly diverse alleles is analogous to the "shared epitope hypothesis" proposed in subjects with rheumatoid arthritis (25, 26) . The "shared epitope" is a conserved amino acid sequence ( 70 R/Q-R/K-R-A-A 74 ) present in the HLA-DRβ chain of a group of several HLA-DR variants that, collectively, exhibit a strong association with the development of rheumatoid arthritis (25) . The shared epitope is hypothesized to lead to the presentation of common "arthritogenic" autoreactive peptides (27) , though this has not yet been directly demonstrated. The analysis in RA patients of naturally processed antigenic peptides following our experimental approach (NAPA) may provide the evidence to confirm common arthritogenic peptide presentation in patients with shared epitope alleles. Although the collective analysis of alleles carrying a common motif has not yet been widely adopted for genetic studies in scleroderma, our data provides strong evidence for a shared epitope-like motif in scleroderma and bolsters the rationale for the use of such analyses in future studies.
The identification of the shared presentation of multiple TOP1 epitopes has also enabled the definition of two distinct groups of TOP1 peptides that differ in their interaction with HLA-DR. Group A TOP1 peptides contain a single core epitope that is bound in the same register to multiple HLA variants, likely interacting with elements in the peptide binding grove sharing similar features. Group B TOP1 peptides contain multiple distinct epitopes that utilize different anchor residues to bind to diverse HLA variants. While promiscuous peptides have been described in the setting of cancer, infection, and mouse models of autoimmunity (28) (29) (30) (31) (32) , to our knowledge such peptides have not been described to be naturally presented in patients with autoimmunity.
Further biophysical studies are required to define the precise anchor residues responsible for presentation of promiscuous TOP1 peptides in scleroderma, and to determine if this mechanism is operative in other autoimmune diseases.
Although the study of natural antigen processing by mo-DCs revealed a set of immunodominant TOP1 epitopes, this likely does not represent all of the TOP1 epitopes capable of driving pathogenic anti-TOP1 immune responses in scleroderma. There are several technical and biological explanations for this, including that NAPA may not have been able to capture TOP1 peptides that were presented at a low frequency or affinity, reflecting a finite sensitivity of the assay. Moreover, while dendritic cells are the most effective antigen presenting cells in activating T cell responses, other cells like macrophages and B lymphocytes express MHC class II processing machinery and have the ability to present CD4+ T cell epitopes (33) . Therefore, additional TOP1 epitopes could be revealed by studying the processing of TOP1 by other antigen presenting cells.
In addition, presentation of unique autoantigenic epitopes has been observed in resident antigen presenting cells present in disease target tissue in mouse models of diabetes, suggesting that presentation of tissue-specific CD4+ T cell epitopes may also occur (34, 35) . Despite the above limitations, the discovery of immunorelevant TOP1 epitopes presented by mo-DCs and recognized by autoreactive T cells in the majority of patients with ATA-positive scleroderma, likely mirrors the critical role of dendritic cells in initiating a primary autoimmune response to TOP1.
The pathogenic relevance of the convergent presentation of TOP1 epitopes in patients with scleroderma is illustrated by the detection of TOP1-specific CD4+ T cell responses to this core set of epitopes in >70% of patients with ATA-positive scleroderma. We showed enrichment of TOP1epitope-specific T cells in ATA-positive compared to ATA-negative patients, and a significant relationship between the number of TOP1 epitopes recognized and the severity of lung fibrosis.
Unique HLA-DR variants have been significantly linked to scleroderma, and in particular, to specific disease manifestations such as ILD (36) . Importantly, HLA-DRB1*11:01 has shown association with ILD only in the presence of ATA. In a British cohort (37) , the relative risk of developing ILD in patients carrying HLA-DRB1*11:01 was 2.7 (statistically not significant), but this increased to 15.8 in subjects with both HLA-DRB1*11:01 and positive ATA. Together with the evidence provided by our study, this suggests a model where specific HLA variants are mechanistically linked to the development of scleroderma ILD by favoring the selection of TOP1specific autoreactive T cells.
In our previous work, we have shown that the frequency of TOP1-specific CD4+ T cells is associated with the severity of lung fibrosis (11) . This new study extends that observation by successfully defining the epitope-specificity of these autoreactive T cells. We demonstrate that a core set of 10 TOP1 epitopes elicits robust specific T cell responses in the majority of studied ATA positive scleroderma-ILD patients, with the breadth of epitopes recognized inversely associating with lung function. This has significant clinical implications and may inform the development of antigen-specific monitoring and therapeutic tools.
Tetramers made from MHC molecules bound to antigenic peptides can be used to identify, track, and study antigen-specific immune responses over time in peripheral blood, as well as target tissues (38) . In scleroderma patients, TOP1 tetramers could therefore be a precise tool to study the frequency and phenotype of TOP1 specific T cells ex vivo. Longitudinal studies in early scleroderma cohorts will define whether the repertoire of TOP1 epitope-specific CD4+ T cells changes over time and predicts onset or progression of fibrotic lung disease. This is an important unmet need as ILD is among the leading causes of scleroderma-related mortality and no reliable biomarkers is clinically available to predict early on the development and the clinical trajectory of lung involvement (39) . The core set of TOP1 epitopes identified in our investigation can also represent viable candidates for the development of novel antigen-specific therapies. By understanding the polyclonal nature of the autoimmune responses and the advances of medical bioengineering, we can ensure the delivery of biologically relevant epitopes using tools like nanoparticles or other carriers. Such therapies can induce the formation of antigen-specific regulatory networks and have shown promise in pre-clinical models of autoimmune disease and an increasing number of early phase clinical trials (40, 41) .
In this work we successfully leveraged the natural antigen processing machinery of a patient's own antigen presenting cells to define immunorelevant CD4+ T cell epitopes of the autoantigen TOP1. Our findings have implications for our understanding and conceptualization of the development of autoreactive immune responses in scleroderma and other autoimmune diseases. Rather than each individual presenting and recognizing a unique set of autoantigenic peptides, our data supports an alternative model in which a convergent set of self-epitopes is presented by diverse HLA-DR variants, leading to the development of similar autoimmune responses and clinical features.
Materials and Methods
Patient Characterization
Patients in this study were drawn from an observational cohort of patients with scleroderma followed at the Johns Hopkins Scleroderma Center. All patients participating in this study met the 2013 Classification Criteria for Systemic Sclerosis or met at least 3 out of 5 criteria for CREST (i.e. calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia) (42, 43) . The Johns Hopkins institutional review board approved the study and all patients signed written informed consent.
Six ATA-positive patients were recruited for NAPA. For T cell stimulation assays, 11 patients with ATA and 11 patients with either anti-centromere antibodies (ACA) or anti-RNA polymerase 3 (ARA) antibodies, who were negative for ATA, were recruited for this study.
Demographic data, scleroderma subtype (limited versus diffuse skin disease)(43), autoantibody specificities, disease duration from the time of first symptoms (Raynaud or non-Raynaud), smoking status (current), and medication history at the time of the blood draw, were obtained from the Scleroderma Center's database. In order to capture the most developed disease phenotype, the lowest FVC from the pulmonary function test results were utilized. FVC was standardized to age and sex (44, 45) . Any missing clinical information was obtained from a comprehensive review of the electronic medical records. Patients were classified as having limited cutaneous scleroderma, if scleroderma skin sclerosis was restricted to skin distal to the knees and elbows and/or the face, and diffuse cutaneous scleroderma, if skin sclerosis involved the chest, abdomen, and/or proximal extremities (i.e. thighs or upper arms) (43) . The disease duration was calculated both from the first non-Raynaud's disease related symptom as well as from the first occurrence of Raynaud's phenomenon to the time of the serum sample processing. Gastrointestinal involvement was considered present if Medsger score was equal or greater than 1 (46) . ILD was defined based on evidence of pulmonary fibrosis on chest CT. Renal crisis was confirmed by renal biopsy in case of an acute increase in blood pressure. Current immunosuppression was recorded at the time of the blood sampling (prednisone, mycophenolate mofetil, methotrexate, cyclophosphamide, azathioprine, rituximab, tocilizumab). Clinical data are summarized in Table S4 . 
Natural antigen processing assay (NAPA)
Monocyte
Mass Spectrometry Analysis.
Samples were reconstituted in 20 ul of 25% acetonitrile, 0.05% formic acid, and interfering reagents were removed by strong cation exchange (SCX) on a "stage tip" (47) . Peptides were eluted from the SCX tip with 20 ul of 400mM ammonium bicarbonate in 25% acetonitrile and 0.05% formic acid and dried by vacuum centrifugation. Peptides were resuspended by adding 4ul of 10% acetonitrile, 0.1% formic acid, vortexing and diluting with 14 ul of 0.1% formic acid. The entire 18 ul sample was injected onto a 2 cm reverse phase trap (YMC ODS-A 10um particles, 120 Angstroms Kyoto, Japan) and separated on a 75 nm x 20 cm reverse phase column (Reprosil 3um particles, 100A pore size Ammerbuch-Entringen) using 2% to 90% acetonitrile gradient in 0.1% formic acid over 90 mins at 300 nl/min on an EasyLC nanoLC (Thermo Scientific) interfaced with Q-Exactive Plus mass spectrometer (Thermo Scientific).
Eluting peptides were electrosprayed at 2kV, analyzed at 70K resolution (MS) and sequenced by collisional dissociation (HCD) with peptide fragments analyzed at 35K resolution (MS2). Ion target values for MS and MS2 were set at 3e6 and 1e5 with 100 and 150 milliseconds, respectively, and a normalized collision energy of 28. Data files were searched against the 2017 RefSeq83 human database (which contains the TOP1 protein sequence, NP_003277) using PEAKS 7 (Bioinformatic Solutions, Inc.) with the following criteria: 5 ppm mass tolerance for peptide masses; 0.02 daltons for peptide fragments; oxidation of methionine and deamidation of asparagine and glutamine as variable modifications. The database search was performed with no enzyme designation since no exogenous enzyme was added to produce the peptides. The search results were filtered at the 1% (false discovery rate) FDR level using the PEAKS decoy-fusion algorithm.
Histograms were created to determine the length distribution of HLA-DR bound peptides, and peptides derived from keratin or dermcidin were excluded as likely artifactual contaminants.
HLA-DRB1 genotyping and sequence alignment
Whole blood was collected using PAXgene Blood DNA tubes and DNA was extracted according to manufacturer's instructions (PreAnalytiX). High-resolution HLA-DRB1 typing was performed by next generation sequencing at the Johns Hopkins University Immunogenetics Laboratory, as previously described (48) . Amino acid sequences encoded for by the HLA-DRB1 alleles of interest were obtained using the online IMGT/HLA submission tools provided by the Immune Polymorphism Database (IPD) (49, 50) . Peptide contact and pocket residues in each HLA-DRβ1 chain were identified using the online MHC motif viewer (51) . Sequence alignment and consensus sequence visualization was performed using Jalview version 2.10.5 software (52) .
Affinity and register of peptides for HLA-DR variants was predicted using the online NetMHCII 2.3 algorithm (22) .
Protein Structure Images
Linear mapping of patient-specific TOP1 epitopes was plotted using R (R Core Team 
T cell stimulation
Fresh PBMCs from randomly selected ATA-positive (n=11) and ATA-negative patients (n=11) were isolated by Ficoll density-gradient centrifugation (Ficoll-Paque Plus, GE Healthcare).
The cells were resuspended in RPMI medium supplemented with 5% autologous serum, transferred onto a 96-well plate (1.5 × 10 6 cells/well) and cultured at 37 °C, as previously described (11, 23) . Anti-human CD40 blocking antibody (1 ug/ml; G28.5, BioLegend) was added to the cells in order to prevent CD154 internalization. PBMCs were then stimulated for 18 hours using 2.5 uM of each candidate TOP1 peptide (Table 1) 
Statistical analyses
The naturally presented peptides were analyzed using the PANTHER 14.1 gene list analysis tool statistical overrepresentation test for "biological processes". This was performed to determine if the naturally processed peptides were derived from proteins involved in specific processes and too identify those biological processes that were over-represented relative to the human genome (53, 54) . The "GO biological processes complete" annotation set was queried and the FDR and Fisher's exact p-value for each pathway was calculated. The median number of peptides eliciting positive responses in ATA-positive versus ATA-negative patients was compared using a Mann-Whitney test. A cutoff of greater than the 95 th percentile of the responses observed amongst the ATA-negative patients (%CD154+CD4+Tcells > 0.015%) was used to define a positive CD4+ T cell response to antigen stimulation. The association between minimum FVC and the number of stimulatory TOP1 epitopes was analyzed using the Spearman's rho test. The association between minimum FCV and the percentage of TOP1-specific CD154+CD4+ T cells was analyzed using the Pearson's r. Statistical analyses were performed using Prism version 7.03 (Graphpad) and Stata version 14.2 (Stata Corp) software. Statistical significance was defined as a two-sided p-value ≤0.05 throughout.
Fig. 6. Distribution of CD4+ T cell responses to naturally presented TOP1 epitopes in scleroderma. (A) %CD154+CD4+ T cell responses over background observed with media alone
for 11 ATA-positive and 11 ATA-negative scleroderma patients for each of the 10 naturally processed TOP1 peptides identified using NAPA are shown. The dotted line represents the cutoff for positivity that was defined as >95 th percentile of the T cell responses observed in ATAnegative patients (95 th percentile=0.015%). Each unique colored symbol represents a different patient. (B) The number of peptides eliciting a response in ATA-positive (n=11) and ATAnegative (n=11) scleroderma patients is shown (Mann-Whitney, p=0.02). A p-value <0.05 was considered significant throughout. Open symbols represent patients that possess at least one previously defined ATA-associated HLA-DRB1 allele. Fig. 7 . Clinical significance of CD4+ T cell responses to naturally presented TOP1 epitopes in scleroderma. The minimum FVC (% of expected) was plotted against (A) the number of TOP1 epitopes eliciting a T cell response and (B) the percentage of CD154+CD4+ T cells responses elicited against the whole TOP1 protein in ATA-positive scleroderma patients with clinically documented ILD (n=9). The correlation between minimum FVC and the number of stimulatory TOP1 epitopes was analyzed using a Spearman's rho test, and the correlation with the magnitude of the T cell responses to the TOP1 protein was analyzed using a Pearson's r test. A p-value <0.05 was considered significant throughout. Table S1 . Mass Spectrometry Analysis of peptides eluted from mo-DCs of 6 ATA-positive Scleroderma patients using anti-HLA-DR antibody to immunoprecipitate the HLA-DR:peptide complexes (Excel file). Table S2 . Mass Spectrometry Analysis of peptides eluted from unpulsed mo-DCs using anti-HLA-DR antibody to immunoprecipitate the HLA-DR:peptide complexes (Excel file). Table S3 . Mass Spectrometry Analysis of peptides eluted from mo-DCs using anti-HLA-DR or isotype control antibody to immunoprecipitate the HLA-DR:peptide complexes (Excel file). Table S4 . Demographic and clinical characteristics of the ATA-positive and ATA-negative SSc patients used for T cell stimulation assays. Table S5 . CD4+ T cell responses of ATA-positive and ATA-negative scleroderma patients to TOP1 peptides identified using NAPA. Figure S1 . TOP1 peptide-specific T cell responses compared to T cell responses to whole TOP1
protein Table S4 . Demographic and clinical characteristics of the ATA-positive and ATA-negative SSc patients included in T cell stimulation assays.
Fig. S1. TOP1 peptide-specific T cell responses compared to T cell responses to whole TOP1 protein. (A)
Frequency of CD154+CD4+ T cells against whole TOP1 molecule between 11 ATA-positive and 11 ATA-negative SSc patients. (B) The proportion CD154+CD4+ T cell responses against Group A TOP1 peptides (dark blue) or Group B TOP1 peptides (dark green) out of the total CD154+CD4 T cell response to whole TOP1 protein (grey) is shown for each patient.
